Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

News | January 07, 2013
January 7, 2013 — Biosensors International has announced enrollment of the first patient in LEADERS FREE, a clinical...
abbott Xience Xpedition stent
Feature | January 03, 2013
January 3, 2013 — Abbott announced that the Xience Xpedition everolimus-eluting coronary stent system received U.S....
2012 Top 10 Advances in Heart Disease and Stroke Research
Feature | December 28, 2012
December 28, 2012 — Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices...
News | December 20, 2012
December 20, 2012 — The first patient has been enrolled in the Boston Scientific EVOLVE II clinical trial, which is...
Cook, Zilver PTX, stent, expanding, delivery sheath

The Cook Zilver PTX stent expanding from its delivery sheath.

Technology | November 15, 2012
November 15, 2012 — The U.S. Food and Drug Administration (FDA) granted market clearance for Cook Medical’s Zilver PTX...
Boston Scientific Promus Element Plus Promus Element Drug Eluting Stent
News | November 09, 2012
November 9, 2012 — Boston Scientific Corp. has received approval to update the directions for use (DFU) labeling for...
Feature | October 31, 2012
October 31, 2012 — Boston Scientific Corp. received CE mark approval for the Synergy everolimus-eluting platinum...
News | September 17, 2012
September 17, 2012 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report...
News | August 20, 2012
August 20, 2012 — Abbott today announced that the Xience Xpedition everolimus-eluting coronary stent system received CE...
Feature | July 17, 2012 | Kamran Zamanian, Ph.D.
  As the average age of the U.S. population and the number of patients at high risk for cardiovascular disease increase...
News | June 21, 2012
June 21, 2012 — Plans for a new study involving BioFreedom, the polymer-free drug-coated stent (DCS) from Biosensors,...
News | June 15, 2012
June 15, 2012 — Stentys SA, a medical technology company commercializing the world's first and only self-apposing stent...
Feature | June 05, 2012 | Gavin Hays, CEO, Springboard Inc.
Evaluating the performance of your cath lab is key to developing a strategic plan for improving service offerings,...
Technology | June 04, 2012
June 4, 2012 — Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) regulatory approval of 32...
News | May 30, 2012
May 30, 2012 - According to study results to be featured in the late-breaking clinical trials session at the American...